They target the same outcome (tissue repair) through different mechanisms : BPC-157: local growth factor expression, fibroblast stimulation, angiogenesis at the injury site TB-500: systemic cell migration, actin regulation, reduction of chronic inflammation throughout the body Standard Wolverine stack: BPC-157: 250500 mcg SC twice daily , injected near the injury site where possible TB-500: 22.5 mg SC twice weekly loading (weeks 14), then 2 mg weekly maintenance (weeks 512) CRITICAL: do not mix in the same vial - they can be injected in the same session but must remain in separate solutions
The presence of macrophages in VAT contributes significantly to this phonotype
Distribution studies using radiolabeled [3H]BPC-157 demonstrate rapid and widespread tissue distribution following systemic administration
Standard AOD-9604 Dosing Protocol Subcutaneous Injection Dosing: Beginner: 250 mcg per dose, once daily Intermediate: 300-400 mcg per dose, once daily or divided into two doses Advanced: 500 mcg per dose, once daily or 250 mcg twice daily Oral Administration Dosing (if using oral formulation): Standard: 1-2 mg per dose, once daily on empty stomach Higher protocols: Up to 5-10 mg daily, as studied in clinical trials Frequency: Once daily (morning preferred) or twice daily (morning and early afternoon) Timing: Best administered on an empty stomach, typically upon waking or before exercise Cycle Length: 12-16 weeks for initial assessment, with potential for longer protocols based on response Off Cycle: 4-8 weeks between cycles, though not strictly required based on current research Note: Start at the lower end of the dosing range to assess individual tolerance
